Allergy Therapeutics PLC Hardman Research: Continuing to gain market share
October 10 2017 - 2:15AM
RNS Non-Regulatory
TIDMAGY
Allergy Therapeutics PLC
10 October 2017
Hardman Research: Continuing to gain market share
Continuing to gain market share - AGY is a long-established
specialist in the prevention, diagnosis and treatment of allergies.
Pollinex Quattro continues to gain market share despite being
available in the EU only on a 'Named Patient' basis. Investment in
marketing over the last three years has been reflected in
exceptional growth, with +10% CAGR in sales over the last five
years compared to overall allergy vaccine market growth of +1%. In
fiscal 2017, AGY gained another one-point market share to 13%.
R&D investment in clinical trials for full approval as a
biological in both Europe and the US are progressing with results
due to be released in the second half of calendar 2018.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/10.10.17-continuing-to-gain-market-share.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea www.hardmanandco.com
EC2M 1NH Hill
Follow us on Twitter Dr Gregoire
@HardmanandCo Pave
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXENEFFXFFF
(END) Dow Jones Newswires
October 10, 2017 02:15 ET (06:15 GMT)
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024